The FDA has granted de novo authorization to Fifth Eye Inc. for its Analytic for Hemodynamic Instability (AHI), a machine learning (ML)-based, real-time indicator of patient deterioration. Commercialization of the software device, which continuously monitors patients with an electrocardiogram (ECG) for signs of deterioration, got underway on March 1.

Asalyxa Bio Inc. has closed on an oversubscribed seed financing of more than $2 million designed to advance its lead candidate, ASX-100, into the clinic in acute respiratory distress syndrome.

An Australian-led study reported in the January 25, 2021, online edition of Nature Immunology has identified a new immunomodulatory pathway within the gut-lung axis that enhances microbial tyrosine metabolism, which could be targeted to treat or prevent atopic asthma and other inflammatory diseases.